Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Martin C Müller"'
Autor:
Wiltrud Haaß, Helga Kleiner, Christel Weiß, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Rüdiger Hehlmann, Wolf-Karsten Hofmann, Alice Fabarius, Wolfgang Seifarth, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, German CML Study Group
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0129648 (2015)
Unbalanced (major route) additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukemia (CML) indicate an increased risk of progression and shorter survival. Moreover, newly arising ACA under imatinib treatment and clonal evolution
Externí odkaz:
https://doaj.org/article/f121bb6eca144f35b1cf7854cf9ad6dc
Autor:
Wiltrud Haaß, Helga Kleiner, Martin C Müller, Wolf-Karsten Hofmann, Alice Fabarius, Wolfgang Seifarth
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0133769 (2015)
ESPL1/Separase, an endopeptidase, is required for centrosome duplication and separation of sister-chromatides in anaphase of mitosis. Overexpression and deregulated proteolytic activity of Separase as frequently observed in human cancers is associate
Externí odkaz:
https://doaj.org/article/0ae70782c5b54ec98a47e9f9b5b718c0
Autor:
Martin C. Müller, Jorge Cortes, Charles Chuah, Daniel Deangelo, Michael Deininger, François Guilhot, Timothy Hughes, Franck Emmanuel Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Neil P. Shah, Moshe Talpaz, Vickie Lu, Thihan Padukkavidana, Hagop Kantarjian
Publikováno v:
HemaSphere, Vol 7, p e88427a9 (2023)
Externí odkaz:
https://doaj.org/article/eb3dd58a194242debe7a5d6162af5c8c
Autor:
Parimala Sonika Godavarthy, Rahul Kumar, Stefanie C. Herkt, Raquel S. Pereira, Nina Hayduk, Eva S. Weissenberger, Djamel Aggoune, Yosif Manavski, Tina Lucas, Kuan-Ting Pan, Jenna M. Voutsinas, Qian Wu, Martin C. Müller, Susanne Saussele, Thomas Oellerich, Vivian G. Oehler, Joern Lausen, Daniela S. Krause
Publikováno v:
Haematologica, Vol 105, Iss 1 (2020)
The endosteal bone marrow niche and vascular endothelial cells provide sanctuaries for leukemic cells. In murine chronic myeloid leukemia (CML) CD44 on leukemia cells and E-selectin on bone marrow endothelium are essential mediators for the engraftme
Externí odkaz:
https://doaj.org/article/222bdee963a84eddb009ae8905b3bf47
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Supplementary Table 2. Outcome comparison in patients recruited to the IRIS, German CML IV and SCREEN studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c9cf50cc01614176bfe84fab65afa3
https://doi.org/10.1158/1078-0432.22466630.v1
https://doi.org/10.1158/1078-0432.22466630.v1
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Figure 5. Nomograms predicting eight-year FFS probabilities according to BCR-ABL/GUSIS expression at diagnosis and the Sokal (panel A) or Hasford (panel B) prognostic scores were generated by stratifying patients for these variables and then using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b9a5125d1b05bcd85f1dc536a80d25
https://doi.org/10.1158/1078-0432.22466636
https://doi.org/10.1158/1078-0432.22466636
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Figure 2. Comparison of BCR-ABL/ABL levels at diagnosis in patients achieving an OR or failing IM. Patients were stratified according to their IM response scored following the 2013 ELN criteria (optimal vs failure). BCR-ABL transcripts - using ABL as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::316810f32868ac0437d9b13f98fc43e1
https://doi.org/10.1158/1078-0432.22466645.v1
https://doi.org/10.1158/1078-0432.22466645.v1
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Figure 1. Eight-year estimates, in an intention-to-treat analysis, for OS (solid line) and TFS (dashed line) in 272 CML patients receiving IM 400 mg/daily as first line therapy. At 60 months, OS was 93%, while TFS was 97.5%. Vertical lines indicate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b0560ea37b3273a263ac5f9df0472b
https://doi.org/10.1158/1078-0432.22466648
https://doi.org/10.1158/1078-0432.22466648
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline molecular parameters associated with inadequate imatinib responses.Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb685c1e405a1a2ef9c6948216b5ec6
https://doi.org/10.1158/1078-0432.c.6526382
https://doi.org/10.1158/1078-0432.c.6526382
Autor:
Francesco Di Raimondo, Andreas Hochhaus, Martin C. Müller, Livia Manzella, Bruno Martino, Stefano Molica, Fortunato Morabito, Maurizio Musso, Pamela Murgano, Carmela Tomaselli, Giuseppe Mineo, Alessandra Malato, Caterina Musolino, Stefana Stella Impera, Donato Mannina, Sergio Siragusa, Agostino Antolino, Michele Massimino, Stefano Forte, Alessandra Cupri, Stefania Stella, Fabio Stagno, Paolo Vigneri
Figure 4. Evolution of BCR-ABL/ABL transcripts in CML patients displaying high (A) or low (B) BCR-ABL/GUSIS levels at diagnosis according to the FFS threshold indicated in Table 1. Asterisks in the upper graph indicate confirmed transcript values in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82444e5107f2052fe532248e1345845c
https://doi.org/10.1158/1078-0432.22466639.v1
https://doi.org/10.1158/1078-0432.22466639.v1